Nerlynx (neratinib tablets - Puma) — Cigna

Initial criteria

• Patient age ≥ 18 years AND
• Patient has HER2-mutant disease AND
• Patient has recurrent or metastatic disease AND
• Patient has tried at least one systemic regimen (e.g., pembrolizumab, atezolizumab, cisplatin, paclitaxel, bevacizumab, topotecan, carboplatin)

Approval duration

1 year